Fate Therapeutics
Fate Therapeutics is a biopharmaceutical company dedicated to developing programmed cellular immunotherapies for cancer and autoimmune diseases. They focus on innovative cell-based therapies using their unique ex vivo cell programming approach, aiming to modulate the therapeutic function and fate of hematopoietic cells. Their mission is to transform the lives of patients with severe, life-threatening diseases by pioneering ground-breaking science and making cell therapy delivery routine and accessible.
Industries
Nr. of Employees
large (251-1000)
Fate Therapeutics
La Jolla, California, United States, North America
Products
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines used to develop off-the-shelf cellular immunotherapies.
FT819
An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19 for treating systemic lupus erythematosus and other autoimmune diseases.
FT819
An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19 for treating systemic lupus erythematosus and other autoimmune diseases.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines for developing off-the-shelf cellular therapies.
iPSC Platform
A proprietary platform for creating genetically engineered, clonal master iPSC lines used to develop off-the-shelf cellular immunotherapies.
FT819
An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19 for treating systemic lupus erythematosus and other autoimmune diseases.
FT819
An off-the-shelf, iPSC-derived CAR T-cell product candidate targeting CD19 for treating systemic lupus erythematosus and other autoimmune diseases.